Limits...
Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Oh MS, Cho KH, Kim MC, Hachinohe D, Hwang SH, Lee MG, Sim DS, Park KH, Kim JH, Ahn Y, Kang JC - Korean Circ J (2012)

Bottom Line: Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes.Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

View Article: PubMed Central - PubMed

Affiliation: The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

ABSTRACT

Background and objectives: Non-high density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) are markers of atherosclerotic risk and predictors of cardiovascular events. The aim of this study was to evaluate clinical impact of non-HDL-C and ApoB on clinical outcomes in metabolic syndrome (MS) patients with acute myocardial infarction (AMI) undergoing percuatneous coronary intervetion.

Subjects and methods: We analyzed 470 MS patients (64.4±12.0 years, 53.6% male) with AMI who were followed-up for 12-month after percutaneous coronary intervention (PCI) from December 2005 to January 2008 in a single center. These patients were divided into 2 groups based on median values of non-HDL-C and ApoB. We studied their baseline and follow-up relation with 12-month clinical outcomes, all-cause death and major adverse cardiac events (MACE).

Results: Mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/dL and 99.3±29.0 mg/dL respectively. During 12-month follow-up 32 MACE (6.8%) and 12 deaths (2.5%) occurred. We observed significant correlation between non-HDL-C and ApoB. Twelve-month MACE and all-cause death after PCI showed no significant relation as non-HDL-C or ApoB levels increased. Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes. Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.

Conclusion: There was no significant association between higher non-HDL-C or ApoB and 12-month clinical outcomes in MS patients with AMI undergoing PCI. ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

No MeSH data available.


Related in: MedlinePlus

Adjusted 12-month survival curves for MACEs. A: baseline non-HDL-C. B: follow-up non-HDL-C. C: baseline ApoB. D: follow-up ApoB. MACE: major adverse cardiac event, non-HCL-C: non-high density lipoprotein-cholesterol, AopB: apolipoprotein B.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3369963&req=5

Figure 1: Adjusted 12-month survival curves for MACEs. A: baseline non-HDL-C. B: follow-up non-HDL-C. C: baseline ApoB. D: follow-up ApoB. MACE: major adverse cardiac event, non-HCL-C: non-high density lipoprotein-cholesterol, AopB: apolipoprotein B.

Mentions: Fig. 1A and B show Cox adjusted survival curves for 12-month MACE of baseline and follow-up non-HDL-C respectively. Fig. 1C and D show Cox adjusted survival curves for 12-month MACE of baseline and follow-up ApoB respectively.


Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Oh MS, Cho KH, Kim MC, Hachinohe D, Hwang SH, Lee MG, Sim DS, Park KH, Kim JH, Ahn Y, Kang JC - Korean Circ J (2012)

Adjusted 12-month survival curves for MACEs. A: baseline non-HDL-C. B: follow-up non-HDL-C. C: baseline ApoB. D: follow-up ApoB. MACE: major adverse cardiac event, non-HCL-C: non-high density lipoprotein-cholesterol, AopB: apolipoprotein B.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3369963&req=5

Figure 1: Adjusted 12-month survival curves for MACEs. A: baseline non-HDL-C. B: follow-up non-HDL-C. C: baseline ApoB. D: follow-up ApoB. MACE: major adverse cardiac event, non-HCL-C: non-high density lipoprotein-cholesterol, AopB: apolipoprotein B.
Mentions: Fig. 1A and B show Cox adjusted survival curves for 12-month MACE of baseline and follow-up non-HDL-C respectively. Fig. 1C and D show Cox adjusted survival curves for 12-month MACE of baseline and follow-up ApoB respectively.

Bottom Line: Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes.Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

View Article: PubMed Central - PubMed

Affiliation: The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

ABSTRACT

Background and objectives: Non-high density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) are markers of atherosclerotic risk and predictors of cardiovascular events. The aim of this study was to evaluate clinical impact of non-HDL-C and ApoB on clinical outcomes in metabolic syndrome (MS) patients with acute myocardial infarction (AMI) undergoing percuatneous coronary intervetion.

Subjects and methods: We analyzed 470 MS patients (64.4±12.0 years, 53.6% male) with AMI who were followed-up for 12-month after percutaneous coronary intervention (PCI) from December 2005 to January 2008 in a single center. These patients were divided into 2 groups based on median values of non-HDL-C and ApoB. We studied their baseline and follow-up relation with 12-month clinical outcomes, all-cause death and major adverse cardiac events (MACE).

Results: Mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/dL and 99.3±29.0 mg/dL respectively. During 12-month follow-up 32 MACE (6.8%) and 12 deaths (2.5%) occurred. We observed significant correlation between non-HDL-C and ApoB. Twelve-month MACE and all-cause death after PCI showed no significant relation as non-HDL-C or ApoB levels increased. Follow-up patients (n=306, rate 65%) also did not show significant relation with clinical outcomes. Twelve-month MACE decreased as non-HDL-C and ApoB reduction rates increased.

Conclusion: There was no significant association between higher non-HDL-C or ApoB and 12-month clinical outcomes in MS patients with AMI undergoing PCI. ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates.

No MeSH data available.


Related in: MedlinePlus